NASDAQ: ARTLArtelo Biosciences Inc Stock
$1.32+0.02 (+1.54%)
Updated Jun 11, 2026
ARTL Price
$1.32
Fair Value Price
-$0.04
Market Cap
$3.08M
52 Week Low
$1.19
52 Week High
$85.80
P/E
-0.04x
P/B
0.46x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.47M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.88
Operating Cash Flow
-$8M
Beta
0.63
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ARTL Overview
Artelo Biosciences, Inc. functions as a clinical-stage biopharmaceutical enterprise dedicated to discovering and advancing therapies that modulate the endocannabinoid system. The company's robust developmental portfolio encompasses several promising candidates: ART27.13, a synthetic G protein-coupled receptor agonist currently undergoing Phase 1b/2a clinical investigation for cancer-related anorexia; ART12.11, a synthetic cannabidiol cocrystal being explored for inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor with potential applications in prostate and breast cancer treatment, as well as PTSD. Further extending its research efforts, Artelo has established a collaborative partnership with Trinity College Dublin to probe ART27.13's efficacy in addressing cancer cachexia. Established in 2011, the entity initially operated under the name Reactive Medical, Inc. before rebranding as Artelo Biosciences, Inc. in April 2017. Its corporate headquarters are situated in Solana Beach, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ARTL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ARTL
Ranked#365 of 463
Ranked#365 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $236.17 | A | |
| $53.50 | A | |
| $15.85 | A |
Be the first to know about important ARTL news, forecast changes, insider trades & much more!
ARTL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ARTL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ARTL ($1.32) is overvalued by 3,444.69% relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
ARTL ($1.32) is not significantly undervalued (3,444.69%) relative to our estimate of its Fair Value price of -$0.04 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ARTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ARTL due diligence checks available for Premium users.
Valuation
ARTL fair value
Fair Value of ARTL stock based on Discounted Cash Flow (DCF)
Price
$1.32
Fair Value
-$0.04
Undervalued by
3,444.69%
ARTL ($1.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ARTL ($1.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ARTL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ARTL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.04x
Industry
17.66x
Market
13.95x
ARTL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.83x
ARTL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ARTL's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.0M
Profit Margin
0%
ARTL's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$12.5M
Liabilities
$5.8M
Debt to equity
0.88
ARTL's short-term assets ($10.42M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ARTL's short-term assets ($10.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ARTL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.2M
Investing
$0.0
Financing
$10.9M
ARTL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ARTL vs Biotech Stocks
Artelo Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.